Difficulty: Medium
Average Score: 87%
Practice
A 10-mo-old boy has a left suprarenal mass. Surgery is accomplished with complete removal of the mass as well as the non-adherent lymph nodes; surgical biopsies are taken during surgery. The histology reveals poorly differentiated neuroblastoma with microscopic ipsilateral lymph nodes involvement. The contralateral lymph nodes are negative. Of the following, the BEST therapeutic approach for this infant is
Correct answer
A
Rationale
In this scenario, the best therapeutic approach for the 10-month-old infant with poorly differentiated neuroblastoma and microscopic ipsilateral lymph node involvement is chemotherapy (Option A).
Chemotherapy is the preferred treatment for neuroblastoma in young children because it can target cancer cells throughout the body, including those that may have spread beyond the primary tumor site. In this case, the presence of lymph node involvement indicates a higher risk of metastasis, making systemic treatment with chemotherapy crucial.
Radiotherapy (Option B) is generally avoided in young children due to the potential long-term side effects on developing tissues and organs. Concomitant chemo-radiotherapy (Option C) may be too aggressive for an infant and can result in serious complications. Chemotherapy followed by radiotherapy (Option D) is not the ideal sequence of treatment in this case as radiotherapy is not the primary choice for neuroblastoma management.
Educationally, understanding the rationale behind choosing chemotherapy in pediatric oncology is essential. It highlights the importance of considering age, tumor characteristics, and potential side effects when determining the most appropriate treatment plan for children with cancer. This case emphasizes the importance of individualized, evidence-based care in pediatric oncology to optimize outcomes while minimizing long-term consequences.
Chemotherapy is the preferred treatment for neuroblastoma in young children because it can target cancer cells throughout the body, including those that may have spread beyond the primary tumor site. In this case, the presence of lymph node involvement indicates a higher risk of metastasis, making systemic treatment with chemotherapy crucial.
Radiotherapy (Option B) is generally avoided in young children due to the potential long-term side effects on developing tissues and organs. Concomitant chemo-radiotherapy (Option C) may be too aggressive for an infant and can result in serious complications. Chemotherapy followed by radiotherapy (Option D) is not the ideal sequence of treatment in this case as radiotherapy is not the primary choice for neuroblastoma management.
Educationally, understanding the rationale behind choosing chemotherapy in pediatric oncology is essential. It highlights the importance of considering age, tumor characteristics, and potential side effects when determining the most appropriate treatment plan for children with cancer. This case emphasizes the importance of individualized, evidence-based care in pediatric oncology to optimize outcomes while minimizing long-term consequences.